Abstract:Ureteral stricture caused by holmium: YAG laser lithotripsy is one of the most challenging issues for urologists. Currently, evidence for rapamycin application in reducing ureterostenosis is not sufficient. This study aimed to assess the inhibition of ureteral stricture of rapamycin-eluting stents in vitro and in vivo . A bilayer drug-eluting ureteral stent consisted of drug blending with poly (lactic-co-glycolic acid) (PU/drug stent), which was over-layered by polycaprolactone (PCL) by ultrasonic atomizing spraying. Stent morphology was observed by scanning electron microscope. A kidney-ureter-bladder model was established to simulate the stents-releasing condition, and high-performance liquid chromatography was used to measure the drug release rate. The inhibitory proliferation was detected by CCK-8. The bladder of rats was injured through electro tome, and stents were implanted for 7, 14, and 28 days. The effects of drug-eluting stents was investigated by hematoxylin-eosin staining, immunofluorescence staining, real-time quantitative polymerase chain reaction and western blot. The bilayer stents could block the burst loss of the drug and maintained a sustained delivery period because of the 5.3 μm thickness of the PCL layer. The relative growth rates of cells plotted inhibitory effect on the proliferation of human urethral scar fibroblast cells. For in vivo results of 28 days, the bilayer stent maintained structural integrity and induced less deposition of crystals, thinner and less lamina propria connective tissues were formed, and α-SMA and TGF-β1 were downregulated. Bilayer rapamycin-eluting stent is significantly effective in alleviating fibrosis in in vitro and in vivo models. Statement of significance The occurrence of ureteral stricture resulting from holmium: YAG laser lithotripsy presents a significant challenge for urologists. Traditional double J stents have not been proven to offer a shorter indwelling time or improved inhibition of tissue blocking. While drug-eluting stents containing rapamycin, paclitaxel, and other substances have been extensively used in treating artery stenosis, there is insufficient evidence supporting their application in reducing ureterostenosis. Consequently, a biodegradable polymer ureteric scaffold incorporating rapamycin was fabricated in this study, employing ultrasonic atomization spraying technology to optimize the bilayers composed of 75/25 poly (lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL). The efficacy of the scaffold was subsequently confirmed through in vitro and in vivo experiments.

Polyethylene Glycol Diacrylate (PEGMA) and Polyvinylpyrrolidone (PVP) Delivering Solifenacine as Super Smooth Coating of Ureteral Stent to Relieve Stent Syndrome: In Vitro and In Vivo Study

Polyethylene Glycol Diacrylate (PEGMA) and Polyvinylpyrrolidone (PVP) Delivering Solifenacine as Super Smooth Coating of Ureteral Stent to Relieve Stent Syndrome:<i> In</i><i> Vitro</i> and<i> In</i><i> Vivo</i> Study

Polyvinylpyrrolidone hydrogel coating for ureteral stent: Safety and performance evaluation

Enhanced Long-Term Performance of Ureteral Stents with Functional Coating: Combating Bacterial Adhesion and Inhibiting Encrustation

Improvement of Hydrophilicity and Formation of Heparin/chitosan Coating Inhibits Stone Formation in Ureteral Stents

A randomized, single-blind, multi-center clinical observational study of a new super lubricath coating catheter latex catheters using in urethral catheterization.

Smart Lubricant Coating with Urease‐Responsive Antibacterial Functions for Ureteral Stents to Inhibit Infectious Encrustation

In vitro and in vivo studies on bacteria and encrustation resistance of heparin/poly-L-lysine-Cu nanoparticles coating mediated by PDA for ureteral stent application

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms

Controlled release of aspirin from SiO2-PEG hybrid coating on 316Lss substrate for the preparation of drug eluting stents

Antistricture Ureteral Stents with a Braided Composite Structure and Surface Modification with Antistenosis Drugs

Preparation of 3,4-Dihydroxy-L-phenylalanine modified organic-inorganic hybrid coatings for drug eluting stents

In vitro and in vivo assessment of a bilayered degradable rapamycin-eluting stent for ureteral stricture caused by holmium: YAG laser lithotripsy

Ureteral Stent Technology: Drug-eluting Stents and Stent Coatings

Preliminary study on arsenic trioxide eluting stent with a heparin-immobilized polyurethane coating

Dual-layer Drug Release System Based on Ureteral Stents Inhibits the Formation of Ureteral Stricture

Drug-Eluting Coronary Stents Coated with Polysulfone-Poly(ethylene Oxide) Block Copolymer by Ultrasonic Spray

A new hydrophilic biodegradable ureteral stent restrain encrustation both in vitro and in vivo

Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-Related Symptoms—outcomes from a Network Meta-Analysis

Chitosan/poly(vinyl Alcohol) Blending Hydrogel Coating Improves the Surface Characteristics of Segmented Polyurethane Urethral Catheters.

In vitro and in vivo study of antibacterial and anti‐encrustation coating on ureteric stents